BR112022000604A2 - Anticorpos caninizados para ctla-4 humana - Google Patents

Anticorpos caninizados para ctla-4 humana

Info

Publication number
BR112022000604A2
BR112022000604A2 BR112022000604A BR112022000604A BR112022000604A2 BR 112022000604 A2 BR112022000604 A2 BR 112022000604A2 BR 112022000604 A BR112022000604 A BR 112022000604A BR 112022000604 A BR112022000604 A BR 112022000604A BR 112022000604 A2 BR112022000604 A2 BR 112022000604A2
Authority
BR
Brazil
Prior art keywords
antibodies
human ctla
caninized antibodies
caninized
human
Prior art date
Application number
BR112022000604A
Other languages
English (en)
Portuguese (pt)
Inventor
Ian Tarpey
Mohamad Morsey
Yuanzheng Zhang
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112022000604A2 publication Critical patent/BR112022000604A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112022000604A 2019-07-15 2020-07-15 Anticorpos caninizados para ctla-4 humana BR112022000604A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962874287P 2019-07-15 2019-07-15
PCT/EP2020/069924 WO2021009188A1 (en) 2019-07-15 2020-07-15 Caninized antibodies to human and canine ctla-4

Publications (1)

Publication Number Publication Date
BR112022000604A2 true BR112022000604A2 (pt) 2022-03-03

Family

ID=71620455

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000604A BR112022000604A2 (pt) 2019-07-15 2020-07-15 Anticorpos caninizados para ctla-4 humana

Country Status (8)

Country Link
US (1) US12552864B2 (https=)
EP (1) EP3999539A1 (https=)
JP (2) JP7695228B2 (https=)
CN (2) CN114174336B (https=)
AU (1) AU2020312687A1 (https=)
BR (1) BR112022000604A2 (https=)
CA (1) CA3145347A1 (https=)
WO (1) WO2021009188A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021009188A1 (en) * 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies to human and canine ctla-4
US20240209096A1 (en) 2022-12-27 2024-06-27 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
AU2024210302A1 (en) 2023-01-20 2025-09-04 Invetx, Inc. Bispecific binding agents for use in companion animals
CN120137035A (zh) * 2023-12-06 2025-06-13 北京伟杰信生物科技有限公司 一种抗犬pd-1抗体及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US6703360B2 (en) * 2000-04-07 2004-03-09 Heska Corporation Compositions and methods related to canine IgG and canine IL-13 receptors
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7261890B2 (en) * 2001-12-21 2007-08-28 Idexx Laboratories, Inc. Methods for using canine immunoglobulin variable domains and caninized antibodies
BRPI0509274A (pt) 2004-03-26 2007-09-04 Pfizer Prod Inc usos de anticorpos anti-ctla-4
PL2108132T3 (pl) * 2007-01-15 2018-08-31 Rapiscan Systems, Inc. Systemy wykrywające
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
CA2754408A1 (en) 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013054127A1 (en) * 2011-10-13 2013-04-18 Nvip Pty Ltd Canine/feline cd20 binding epitope and compositions for binding thereto
CA2875783C (en) 2012-06-06 2018-12-11 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
CN106029697B (zh) 2013-12-20 2021-06-04 英特维特国际股份有限公司 具有经修饰的ch2-ch3序列的犬抗体
CN107074952B (zh) 2014-09-30 2021-04-09 英特维特国际股份有限公司 结合犬pd-l1的pd-l1抗体
CA2980087A1 (en) * 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
WO2017062615A2 (en) 2015-10-08 2017-04-13 Macrogenics, Inc. Combination therapy for the treatment of cancer
IL260021B (en) * 2015-12-14 2022-09-01 Macrogenics Inc Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
CA3005696A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2018037092A1 (en) * 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
JP2022500037A (ja) * 2018-09-14 2022-01-04 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための抗ｉｌ４受容体抗体
WO2021009188A1 (en) * 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies to human and canine ctla-4

Also Published As

Publication number Publication date
JP2025081549A (ja) 2025-05-27
US12552864B2 (en) 2026-02-17
CA3145347A1 (en) 2021-01-21
CN114174336B (zh) 2024-10-11
US20220251209A1 (en) 2022-08-11
CN119307505A (zh) 2025-01-14
CN114174336A (zh) 2022-03-11
EP3999539A1 (en) 2022-05-25
WO2021009188A1 (en) 2021-01-21
JP7695228B2 (ja) 2025-06-18
AU2020312687A1 (en) 2022-01-27
JP2022541767A (ja) 2022-09-27

Similar Documents

Publication Publication Date Title
BR112022000604A2 (pt) Anticorpos caninizados para ctla-4 humana
CL2021003327A1 (es) Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089).
CY1123791T1 (el) Μονοκλωνικο αντισωμα ιντερλευκινης-31
BR112019002282A2 (pt) anticorpo que se liga a pd-l1 ou um fragmento de ligação ao antígeno do anticorpo, método para produzir o mesmo e composição para prevenção ou tratamento de câncer ou doenças infecciosas
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
EA201792451A1 (ru) Антитела к ox40 и способы их применения
CR20200467A (es) Agentes anticuerpos anti-cd25
CL2021003535A1 (es) Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional de solicitud 3095-2019)
PH12018500233B1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
CR20230170A (es) ANTICUERPOS ANTI-TREM2 Y MÉTODOS PARA UTILIZARLOS (divisional 2019-0485)
MX2024006398A (es) Animales no humanos geneticamente modificados para generar anticuerpos terapeuticos contra complejos peptidos-mhc, metodos de elaboracion y usos de estos.
JOP20200343A1 (ar) بروتين ربط مولد ضد مضاد لـ steap1
BR112013027420A2 (pt) "uso de camundongos geneticamente modificados na preparação de um anticorpo e método para produzir anticorpos".
MX2023001726A (es) Anticuerpos anti-c5 y usos de los mismos.
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
BR112018068898A2 (pt) anticorpo ou fragmento e seus usos, animal transgênico, hibridoma, vetor, composição farmacêutica e seu uso, método para modular uma doença, método para tratar perda de peso, método para modular atividade
MX2021009975A (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer.
BR112014027291A2 (pt) composições de anticorpos pan-her humanizados
BR112017021484A2 (pt) anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
BR112021025077A2 (pt) Anticorpos anti-sortilina para uso em terapia
CO7240362A2 (es) Molécula de unión il-6
BR112022011570A2 (pt) Anticorpos anti-mertk e métodos de uso dos mesmos
IL277429A (en) Neutralizing monoclonal antibodies with high affinity for PD-L1 and their uses
BR112022000721A2 (pt) Anticorpos caninizados contra ctla-4 canina
WO2019246176A8 (en) Anti-factor xii/xiia antibodies and uses thereof